Literature DB >> 1466203

Distribution of IgG subtypes in maternal anti-D sera and their prognostic value in Rh haemolytic disease of the new-born.

Y S Iyer1, S V Kulkarni, S C Gupte.   

Abstract

In 107 Rh(D)-immunized women having Rh(D)-positive pregnancy screening for IgG subtypes was carried out between the 34th and 36th week of gestation. Using polyclonal IgG subtype-specific reagents, all four IgG subclasses were detected in anti-D sera though IgG1 and IgG3 were the most predominant classes. IgG3 anti-D was usually low titre. At the same level of Rh(D) antibody titre, haemolytic disease of the new-born was more severe when anti-D was IgG1 type than IgG3 type. When the IgG1 and IgG3 anti-D subtypes existed together, the risk of having a stillborn child was very high compared to other subtypes (IgG1 + IgG3 34.8%, IgG1 19.2% and IgG3 15.4%).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466203     DOI: 10.1159/000204656

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

1.  Advances in detection of antenatal alloimmunization and its management.

Authors:  Snehalata C Gupte
Journal:  Asian J Transfus Sci       Date:  2015-04

2.  Prognostic Significance and Prevalence of IgG Subtypes in Rh Haemolytic Disease of Fetus and Newborn.

Authors:  Bharat Singh; Rajendra Chaudhary; Rahul Katharia; Mandakini Pradhan
Journal:  Indian J Hematol Blood Transfus       Date:  2021-03-03       Impact factor: 0.915

3.  IgG Subclass Determines Suppression Versus Enhancement of Humoral Alloimmunity to Kell RBC Antigens in Mice.

Authors:  Paurvi Shinde; Heather L Howie; Tamara C Stegmann; Ariel M Hay; Hayley R Waterman; Zoltan Szittner; Arthur E H Bentlage; Linda Kapp; Suzanne N Lissenberg-Thunnissen; Gillian Dekkers; Richard B M Schasfoort; Sarah J Ratcliffe; Mark E Smolkin; Gestur Vidarsson; C Ellen van der Schoot; Krystalyn E Hudson; James C Zimring
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.